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Abstract
Background: Primary Biliary Cirrhosis is known to be associated with Urinary Tract Infections (UTIs), but whether
these precede or follow the liver disease is unclear. We have therefore attempted to determine whether UTIs are
more common in people with Primary Biliary Cirrhosis (PBC) prior to their diagnosis.
Methods: We conducted a case control study in the General Practice Research Database. All cases of PBC first
recorded at least one year after entry to the dataset were selected along with up to 10 controls matched for age,
sex. A second unmatched control group who had Chronic Liver Diseases but not PBC were chosen. The main
exposures studied were the occurrence of Urinary tract infections and pyelonephritis at least one or at least five
years before diagnosis. We also performed an analysis restricted to those younger than 55 at diagnosis, as we
hypothesized the relationship to be stronger in the younger age group.
Results: PBC is associated with UTI prior to diagnosis, OR 1.50 (CI 1.26-1.78), which was similar 5 years prior to
diagnosis and after adjusting for smoking. The strongest relationships were observed in pyelonephritis exposures
five years before diagnosis in cases under 55 years: adjusted odds ratios were 2.60 (1.02-6.63) in comparison with
matched general population controls and adjusted odds ratios were OR 2.45 (1.02-5.59) in the comparison with
chronic liver disease controls.
Conclusions: We found that the association between urosepsis and PBC is specific to this disease and precedes
the diagnosis of PBC in a manner not previously observed in human data. This is consistent with a causal
relationship.
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Background
Primary Biliary Cirrhosis (PBC) is an idiopathic chronic
liver disease associated with destruction of small intra-
hepatic bile ducts [1]. Both genetic [2] and environmen-
tal factors [3] have been implicated in its aetiology but
no complete explanation is yet accepted. It seems how-
ever likely that the aetiology is a complex interplay
between multiple factors.
There has been recent epidemiological interest in the
spatio-temporal clustering of cases, which might indicate
involvement of a transient toxic or transmissible agent
[4,5]. The agent involved however is as yet uncertain. A
number of potential infectious precipitants have
however previously been considered [6] including organ-
isms such as Mycoplasma [7] and Novosphingobium.aro-
maticivorans[8]. Another group of infections which have
received attention are Urinary Tract Infections (UTIs)
[9]. A number of studies have suggested a specific link
with Escherichia .Coli[10,11] which is the commonest
urinary isolate in the UK [12], and it has been suggested
that this may occur via a mechanism of molecular
mimicry [13]. Epidemiologically it has been known for
some time, that patients with PBC are at increased risk
of urinary tract infection after diagnosis [14] and four
case control studies in recent years have confirmed the
presence of an association [15-18]. They have been
unable however to clearly suggest whether it is a cause
or consequence of PBC since all of these studies have
been retrospective case control studies with exposure to
UTI ascertained by questionnaire at unspecified points
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any medium, provided the original work is properly cited.in the disease course; i.e. at any time during life. In each
study therefore, it is possible that the UTIs recorded
occurred after diagnosis, rather than before onset of the
disease, and each was inevitably susceptible to recall
bias. Since an exposure can be the cause only of out-
comes which occur after it, this means that one cannot
ascribe causality based upon these studies. Further
though Burroughs and colleagues, in their pioneering
work in this area, showed that after diagnosis PBC was
associated with UTI in a manner not seen for other
chronic liver disease [14], such specificity would also
need to be shown for any antecedent association if it
were to be believed causal.
We have therefore set out to establish whether the
epidemiology of the relationship between PBC and UTI
is consistent with a causal relationship both by better
defining the temporal relationship between PBC and
UTI and by establishing whether any relationship is spe-
cific to PBC among liver disease. To achieve this we
have carried out a large population based case-control
study nested in the United Kingdom General Practice
Research Database.
Methods
The United Kingdom General Practice Research Data-
base (GPRD) is a large longitudinal database of primary
care records with data from 1987 until the present [19].
It has over 50 million patient years of data and is con-
stantly being updated by primary care physicians. Parti-
cipating practices contribute anonymised data for
patients including demographics, all major illnesses,
diagnoses, prescriptions, their indications and reason for
withdrawal [19]. Data, which then meets the quality
indicators set by GPRD is termed “up to standard” and
it is this data which has been used to derive our cases,
controls, exposures and covariates. It has been validated
by several studies as a high quality dataset which accu-
rately reflects a range of diagnoses [19,20].
Study design
We constructed an individually matched case control
study nested within GPRD, and using the same cases a
second unmatched case control study. Cases were all
incident cases of PBC in GPRD. These were defined as
those with READ/OXMIS codes for PBC (READ Pri-
mary Biliary Cirrhosis or OXMIS code PRIMARY BILI-
ARY CIRRHOSIS (LIVER)) or Anti-mitochondrial
antibody (AMA) alongside another code for chronic
liver disease or cholestatic liver function tests with
AMA or PBC first recorded at least one year after the
start of the subject’su pt os t a n d a r dd a t af r o mJ a n u a r y
1987 to October 2008. General population controls
matched for age, sex and practice were selected at a
ratio of approximately 10:1. A second group of
unmatched controls who had Chronic Liver Diseases
(CLD) but not PBC were selected to permit assessment
as to whether findings were specific to PBC or were
characteristic of all chronic liver diseases.
Exposures
The primary exposure of interest was the occurrence of
urinary tract infection prior to diagnosis of PBC. To
study this, we abstracted data on the occurrence of epi-
sodes of Urinary Tract Infections (UTI) and of Pyelone-
phritis from the GPRD record using READ and OXMIS
codes for diagnoses. These events were used to categor-
ise subjects as having ever had a UTI or Pyelonephritis
occurring at least a year before diagnosis, and occurring
at least five years before diagnosis.
Potential confounders
We considered age, gender, smoking status, and diabetes
as potential confounders. For the general population
control group, the data was matched for age and gender
which are both known to be important risk factors in
PBC [21]. For the analysis using the chronic liver con-
trol disease group we divided age into 4 bands which
produced rough quartiles (less than 45 years at diagno-
sis, 45-55 years, 55-60 years and over 60 years). Smok-
ing, which is known to be more prevalent in patients
with PBC and is considered to be an important risk fac-
tor for it [15,16], was categorised as ever smoked, never
smoked or missing data on smoking at least a year
before diagnosis. Finally diabetes as a known risk factor
for the development of urinary tract infections [22], was
assessed as a potential confounder categorized as ever
or never having a diagnosis of diabetes.
Analysis
All analyses were conducted using STATA10.1/SE. We
conducted initial descriptive analyses of the data to pro-
duce summary measures of the primary and potentially
confounding exposures. Univariate analyses using both
general population and CLD controls were conducted
using conditional logistic regression for the matched
control group and logistic regression for the unmatched
controls. We then went on to conduct multivariate
regression analyses to assess the effect of smoking in the
matched controls. As the CLD controls were
unmatched, we also adjusted for age and gender to
remove confounding by them. Age and gender were
retained in the final model on an a priori basis, but
other confounders only if their addition or removal
altered the odds ratio by at least 10%. Finally a further
stratified analysis was performed by dividing patients
into those older than or aged 55 years at diagnosis, and
those who were younger than 55 at diagnosis to exam-
ine any possible interaction with age. We hypothesised
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recorded UTI would accurately reflect infection with
Escherichia .Coli was lower due to the potential for mis-
diagnosis of dysuria due to reduced oestrogen levels in
this group. Hence we expected to find a weaker rela-
tionship in those over 55.
Role of the funding source
The data used to conduct this study was provided via an
MRC license. Dr Varyani is an Academic Clinical Fellow
funded by the UK NIHR, Dr Card is funded via a HEFCE
Senior Lectureship Award and Dr West is an NIHR clini-
cian scientist. None of these funders had any role in the
design, conduct, interpretation or writing up of this study.
Ethics
The GPRD Group has ethical approval from a Multi-
centre Research Ethics Committee covering all purely
observational research using GPRD data (including the
current study). The protocol for this project was
approved by the Independent Scientific Advisory Com-
mittee of the GPRD (protocol number 08_068).
Results
We had in total 800 subjects with PBC, 7991 general
population matched controls and 12137 unmatched
chronic liver disease controls. Overall 87% of PBC cases
were female and mean age at diagnosis was 63 years.
Cases had a mean follow up time of 6.5 years and both
sets of controls had a similar amount of follow up time.
The Chronic Liver Disease cohort was younger with a
mean age of 51 years and 40% were female. 44% of the
PBC patients had ever smoked compared to 37% of the
general population controls and 56% of the chronic liver
disease control group. 12% of the PBC patients had ever
had a diagnosis of diabetes compared with 9% of the
controls and 21% of the CLD controls (Table 1). We
found smoking to be associated with prior UTI exposure
and with PBC. Diabetes however was not significantly
associated with UTI or pyelonephritis and its inclusion
in multivariate models did not appreciably alter the
effect estimates for UTI or pyelonephritis. It was hence
not included in the final models.
Overall 229 (29%) of PBC patients had a UTI recorded
in the dataset at least one year before diagnosis, com-
pared to 1737 (22%) of the general population controls
(Table 2). The odds of having a prior diagnosis of UTI
at least one year before diagnosis were 1.50 (CI 1.26-
1.78) times as high for PBC cases as for matched con-
trols. Results were similar for UTIs at least five years
before diagnosis and when the analysis was adjusted for
the potential confounding effects of smoking. When
these analyses were repeated restricting the exposure to
diagnoses of pyelonephritis instead of all UTIs, we
found 14 (1.75%) of the PBC patients had a prior epi-
sode of pyelonephritis compared to 79 (0.99%) of gen-
eral population matched controls. This corresponded to
an unadjusted OR of 1.79 (CI 1.01-3.19) which was
similar when adjusted for smoking. Odds ratios for Pye-
lonephritis five years prior to diagnosis were 1.55 (CI
0.79-3.05), however numbers of cases were small with
only 10 (1.25%) of cases and 66 (0.83%) of controls hav-
ing had Pyelonephritis five years prior to diagnosis.
Using the controls with chronic liver disease produced
on univariate analysis slightly larger estimates of effect
which were reduced when corrected for confounding by
age and gender in UTIs at least a year before diagnosis.
However, these estimates were maintained in UTIs five
years before diagnosis even after adjustment, and were
slightly stronger OR 2.26 (CI 1.28-3.98). Restricting the
chronic liver disease comparison to pyelonephritis expo-
s u r e si n s t e a do fa l lU T I sf o u n d8 5( 0 . 7 0 % )o fc o n t r o l s
with prior pyelonephritis. The unadjusted OR was 2.15
(CI 1.06-3.23) but this changed to 2.35 (CI 0.54-10.24)
after adjustment, and when restricting the comparison
to pyelonephritis exposures five years prior to diagnosis,
only 85 (0.70%) of the controls had an exposure, giving
an unadjusted OR of 1.79 (CI 0.93-3.47) but an adjusted
OR of 5.77(CI 1.15-29.08).
Stratification of UTI occurrence by age groups shows
some interaction between age, frequency of UTIs and
PBC. Formally testing this in our multivariate model
demonstrated this interaction to be significant in UTIs
five years prior to PBC diagnosis (p < 0.05), although a
trend was observable in the other exposures assessed.
We therefore conducted further analyses stratified by
age. Of those patients diagnosed with PBC before the
age of 55, 68 (31%) had a prior diagnosis of UTI (at
least one year prior to diagnosis), compared to 433
(20%) of age and sex matched controls. This corre-
sponds to PBC patients in this age group having odds of
Table 1 Baseline Characteristics for population in study
Cases Match Chronic Liver Disease
N 800 7,991 12,137
% Female 87 87 40
Mean age 63 63 51
% > 55 years 72.3 72.7 49.6
Smoker
Never 46.3 49.7 34.1
Ever 43.8 36.5 55.5
Missing 10.0 13.8 10.4
% Diabetes 12.3 8.9 20.5
Mean followup 6.53 6.25 7.00
Cases are PBC and Match are general population controls matched for age and
sex. Chronic liver disease are those with chronic liver disease who do not have a
diagnosis of PBC, these are unmatched controls
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1.43-2.75). This figure was virtually unchanged by
adjustment of any confounding by smoking, but fell to
an OR of 1.36 (1.11-1.66) among those aged 55 or over
at diagnosis. When comparing to chronic liver disease
controls there was clear confounding by age and gender,
and after adjustment for this, the relationships were
weaker and ceased to be significant (Table 3).
For comparison with both sets of controls, these rela-
tionships were similar if only UTIs at least 5 years
before diagnosis were considered (adjusted OR in those
under 55 of 2.39 (1.67-3.42) for matched and 1.61 (1.15-
2.25) for chronic liver disease controls). Adjusted ORs
for the relationship with Pyelonephritis in those under
55 were 2.60 (1.02-6.63) for matched and 2.45 (1.02-
5.59) for chronic liver disease controls (Table 3).
Discussion
Our study has shown clearly that UTI precedes the
d i a g n o s i so fP B Ca n dt h a tt h i sr e l a t i o n s h i pi sp a r t i c u -
larly strong in younger people with PBC. Overall, people
with PBC were 50% more likely to have had a UTI pre-
viously than their matched controls; this relationship
was maintained five years prior to diagnosis. In addition,
people with PBC are at greater risk of having a prior
UTI than people with chronic liver disease five years
prior to diagnosis.
Though an association between PBC and UTI has pre-
viously been demonstrated, this study moves our knowl-
edge forward in three important respects. Firstly, though
due to the likely long preclinical course of PBC in many
cases, we cannot be sure that UTI predates the onset of
PBC, our data is the first to show evidence of an asso-
ciation prior to diagnosis that extends back at least to 5
years. This is of enormous importance since, only if UTI
does precede PBC can this association be causative. Sec-
ondly we have shown that not all diagnoses of UTI have
equal association with the ri s ko fP B C .U T I sd i a g n o s e d
in younger age groups, may be associated with greater
risk. Thirdly, for UTIs and Pyelonephritis five years
prior to diagnosis, we have shown that this association
is unlikely to be due to better ascertainment of UTIs or
chronic ill health among people with PBC as such a
mechanism should apply equally to other liver diseases.
The current study is, in many ways far stronger than
those which preceded it in other ways as well. Being
Table 2 Odds of UTIs or of Pyelonephritis occurring at least one or at least five years before diagnosis
Matched controls. Chronic liver disease controls
Exposure Case (%) Control (%) OR (CI) Adjusted OR (CI) Control (%) OR (CI) Adjusted OR (CI)
UTI > 1 year 229 (28.63) 1737 (21.74) 1.50 (1.26-1.78) 1.49 (1.25-1.77) 2044 (16.84) 1.98 (1.69-2.33) 1.53 (0.92-2.55)
UTI > 5 years 150 (18.75) 1,095 (13.70) 1.52 (1.24-1.85) 1.50 (1.23-1.84) 1281 (10.55) 1.96 (1.62-2.36) 2.26 (1.28-3.98)
Pyelonephritis > 1 year 14 (1.75) 79 (0.99) 1.79 (1.01-3.19) 1.83 (1.03-3.26) 116 (0.96) 2.15 (1.06-3.23) 2.35 (0.54-10.24)
Pyelonephritis > 5 years 10 (1.25) 66 (0.83) 1.55 (0.79-3.05) 1.55 (0.79-3.05) 85 (0.70) 1.79 (0.93-3.47) 5.77 (1.15-29.08)
The adjusted models are adjusted for diabetes in the comparison to matched controls, and age gender and diabetes in the comparison to chronic liver disease controls.
Table 3 Odds of UTIs and odds of pyelonephritis occurring at least one or at least five years before diagnosis
stratified by age
Matched controls. Chronic liver disease controls
Age groups Case (%) Control (%) OR (CI) Adjusted OR (CI) Control (%) OR (CI) Adjusted OR (CI)
UTIs at least one year before diagnosis
< 55 68 (31.2) 433 (19.9) 1.98 (1.43-2.75) 1.97 (1.42-2.74) 865 (14.1) 2.76 (2.06-3.71) 1.24 (0.91-1.68)
> = 55 161 (27.7) 1304 (22.4) 1.36 (1.11-1.66) 1.34 (1.10-1.64) 1179 (19.6) 1.56 (1.29-1.90) 0.90 (0.74-1.10)
UTIs at least five years before diagnosis
< 55 53 (24.3) 280 (12.9) 2.39 (1.67-3.42) 2.39 (1.67-3.42) 526 (8.3) 3.43 (2.48-4.73) 1.61 (1.15-2.25)
> = 55 97 (16.7) 815 (14.02) 1.25 (0.98-1.60) 1.24 (0.97-1.58) 755 (12.6) 1.39 (1.10-1.75) 0.83 (0.65-1.05)
Pyelonephritis at least one year before diagnosis
< 55 7 (3.21) 34 (1.56) 2.13 (0.92-4.91) 2.16 (0.93-5.02) 60 (0.98) 3.36 (1.52-7.44) 1.87 (0.83-4.19)
> = 55 7 (1.20) 45 (0.77) 1.56 (0.70-3.46) 1.59 (0.71-3.55) 56 (0.93) 1.29 (0.59-2.85) 0.82 (0.37-1.83)
Pyelonephritis at least five years before diagnosis
< 55 6 (2.75) 25 (1.15) 2.54 (1.00-6.46) 2.60 (1.02-6.63) 39 (0.64) 4.42 (1.85-10.56) 2.45 (1.02-5.95)
> = 55 4 (0.69) 41 (0.71) 0.98 (0.35-2.72) 0.99 (0.35-2.76) 46 (0.77) 0.90 (0.32-2.50) 0.58 (0.20-1.62)
The adjusted models are adjusted for smoking in the comparison to matched controls, and with gender and smoking in the comparison to chronic liver disease
controls.
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patients cared for in UK general practice (the population
from which it is drawn), and therefore in essence to the
population of the UK. As it is based upon prospectively
recorded data, there is no potential for recall bias and
since all potential cases for the study were selected, and
controls were chosen in an unbiased manner, selection
bias also cannot realistically occur.
The great weakness of this as of any study based on
an anonymised clinical records database is the potential
for error in the definition of both outcomes and expo-
sures which cannot be validated. For the current out-
come of PBC, we do not have great concern as to error
as we have previously shown that the epidemiology of
PBC when described in this database closely mirrors the
best modern conventional epidemiological studies avail-
able in the UK population [21,23-26]. The possibility of
error in the coding of UTI needs however far closer
attention. One should first note that UTI is itself in this
study in effect being used as a proxy for E. Coli infec-
tion since this is the commonest UK isolate accounting
for about 80% of cases [12] (our hypothesis is of the
induction of autoimmunity by molecular mimicry by
that organism). In addition, a clinical diagnosis (which
for most of the recorded exposures is not supported by
l a b o r a t o r ye v i d e n c e )o fU T Ii sap r o x yf o rat r u eU T I .
We have attempted to address this uncertainty in two
manners. Firstly we have looked at pyelonephritis as a
subset of UTIs far less likely to have been diagnosed
without good evidence of urinary tract infection. This
produced despite limited power and therefore a lack of
significance generally greater estimates of effect than
found for uncomplicated UTI. Secondly we considered
that some urinary symptoms diagnosed as UTI in the
post menopausal might in reality merely represent oes-
trogen deficiency of the urothelial membranes since this
has been shown to be reversibly related to symptoms of
urinary frequency and stress incontinence [27]. We
therefore stratified by age hypothesising that the diagno-
sis would be more secure in the young. Again we found
greater effect where the diagnosis was likely to be more
secure. Taken together we believe these results suggest
that if anything the error in coding of UTI is likely to
have caused a null bias (tending to obscure a true asso-
ciation), which will have been less marked in those with
pyelonephritis or UTIs at earlier age.
Our study has, of course, other weaknesses than that
previously alluded to however. The greatest of these is
that we have data only for a fairly limited time period,
and cannot therefore look more than 5-10 years back
f r o mt h ed i a g n o s i so fP B C .I na d d i t i o n ,w eh a v en o
way to determine the time at which AMA positivity,
or derangement of liver function first occurred, and so
though this study is perhaps the best evidence yet that
UTIs predispose to PBC rather than vice versa, it can-
n o to ni t so w nb er e g a r d e da sc o n c l u s i v e .I ns u p p o r t
of this suggestion there is however some laboratory,
experimental and human evidence regarding the
development of AMAs and PBC in relation to infec-
tions. Though the development of AMAs is not exclu-
sive to E Coli infection (it occurs occurs also with
xenobiotics and other organisms [7,8,28]), a number
of strands of evidence show its potential importance
in this context. Examples of this include rabbits
immunised with rough mutants of E.Coli which devel-
oped antibodies to AMA reactive components [29],
mice infected with recurrent UTIs which developed
AMAs and histology similar to early PBC [30] and the
greater proportion of people with recurrent UTIs
found to be AMA positive compared to the general
population [31].
Conclusion
In conclusion, we have demonstrated a strong associa-
tion between UTI and subsequent diagnosis of PBC,
that this association goes back at least five years before
diagnosis and that it is stronger in younger subjects. In
addition, this finding was specific to PBC when com-
pared to other chronic liver diseases. This work provides
the strongest evidence yet produced that this relation-
ship is indeed a causal one.
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